Oryzon Genomics SA (ORY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oryzon Genomics SA (ORY) has a cash flow conversion efficiency ratio of -0.031x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.41 Million ≈ $-2.82 Million USD) by net assets (€78.54 Million ≈ $91.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oryzon Genomics SA market cap and net worth for the company's overall valuation and market capitalisation.
Oryzon Genomics SA - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Oryzon Genomics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oryzon Genomics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oryzon Genomics SA ranked by their cash flow conversion efficiency. Explore cash flow quality index of Oryzon Genomics SA to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VIA Labs Inc
TW:6756
|
0.033x |
|
Young Fast Optoelectronics Co Ltd
TW:3622
|
0.016x |
|
Global Green Chemicals Public Company Limited
BK:GGC
|
0.057x |
|
Smart Sand Inc
NASDAQ:SND
|
0.014x |
|
Favite Inc
TW:3535
|
0.021x |
|
Dogus Gayrimenkul Yatirim Ortakligi AS
IS:DGGYO
|
0.006x |
|
The Gold Bond Group Ltd
TA:GOLD
|
0.012x |
|
BF Utilities Limited
NSE:BFUTILITIE
|
0.229x |
Annual Cash Flow Conversion Efficiency for Oryzon Genomics SA (2013–2025)
The table below shows the annual cash flow conversion efficiency of Oryzon Genomics SA from 2013 to 2025. View Oryzon Genomics SA (ORY) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €117.85 Million ≈ $137.78 Million |
€-2.36 Million ≈ $-2.75 Million |
-0.020x | +69.41% |
| 2024-12-31 | €87.04 Million ≈ $101.76 Million |
€-5.69 Million ≈ $-6.65 Million |
-0.065x | -829.69% |
| 2023-12-31 | €81.77 Million ≈ $95.60 Million |
€-574.96K ≈ $-672.19K |
-0.007x | +72.38% |
| 2022-12-31 | €72.57 Million ≈ $84.84 Million |
€-1.85 Million ≈ $-2.16 Million |
-0.025x | +49.97% |
| 2021-12-31 | €71.26 Million ≈ $83.31 Million |
€-3.63 Million ≈ $-4.24 Million |
-0.051x | +19.79% |
| 2020-12-31 | €75.93 Million ≈ $88.77 Million |
€-4.82 Million ≈ $-5.63 Million |
-0.063x | -29.04% |
| 2019-12-31 | €80.02 Million ≈ $93.55 Million |
€-3.93 Million ≈ $-4.60 Million |
-0.049x | -233.08% |
| 2018-12-31 | €45.13 Million ≈ $52.76 Million |
€-666.09K ≈ $-778.73K |
-0.015x | +89.20% |
| 2017-12-31 | €34.43 Million ≈ $40.25 Million |
€-4.71 Million ≈ $-5.50 Million |
-0.137x | +37.94% |
| 2016-12-31 | €22.73 Million ≈ $26.57 Million |
€-5.01 Million ≈ $-5.85 Million |
-0.220x | -1262.00% |
| 2015-12-31 | €27.59 Million ≈ $32.26 Million |
€523.14K ≈ $611.61K |
0.019x | -97.83% |
| 2014-12-31 | €13.89 Million ≈ $16.24 Million |
€12.13 Million ≈ $14.18 Million |
0.873x | +6.01% |
| 2013-12-31 | €14.73 Million ≈ $17.22 Million |
€12.13 Million ≈ $14.18 Million |
0.823x | -- |
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more